Patients with refractory, EGFR-undetectable mCRC who had undergone at least one standard chemotherapy regimen containing fluoropyrimidine were given cetuximab in the standard dosage regimen and evaluated for tumor response every six weeks. The gene discussed is EGFR; the disease is neoplasm.